Skip to content

SankoreAfrican research intelligence

Countries
Institutions
Fields
Rankings
Compare

Search institutions, scholars, countries and publications

Sankore

Named after the University of Sankore in Timbuktu — one of the world’s oldest centres of learning. Every figure here is computed from work-level records in our own graph, never copied from a source’s summary count.

Built from

OpenAlex — works, authorships, subject classification
ROR — institutional identity
ORCID — researcher identity
Crossref — publisher confirmation

Browse

Countries
Institutions
Fields
Rankings
What we cover

Coverage is partial and says so. A country appears with its research output only once its works have been swept; until then the portal shows whatever the graph happens to hold for it and labels it as exactly that.

Enayi Onaji · Sankore

Ahmadu Bello University

Enayi Onaji

ORCID, self-asserted

ORCID 0009-0001-4600-6876

This profile carries an ORCID the researcher published on their own record — the strongest evidence available short of a human confirming it.

Publications

3

Citations

1

h-index

1

Computed over the works the graph holds, so it is a floor rather than a career figure.

i10-index

0

Works published 2022 onward have been swept for this country. Figures are complete within that window, to the extent the open indexes are.

Affiliations

Every institution this scholar has appeared with on a work, by how many.

Medical Laboratory Science Council of Nigeria2 works
Ahmadu Bello University2 works

Publications

3 works in the graph, newest first.

Pharmacophore based discovery of dual inhibitors targeting TOP1 and TOP2A in resistant triple negative breast cancer
2026Discover Chemistry.JournalOpen accessFirst authorCorresponding1 citations10.1007/s44371-026-00603-x
Key challenges limiting local vaccine production in Nigeria: A quantitative study among industrial and regulatory pharmacists
2026Vaccine XJournalOpen accessSenior author0 citations10.1016/j.jvacx.2026.100873
Novel Chalcone Derivatives as Potent Lyn Tyrosine Kinase Inhibitors: A Promising In-Silico Approach for Targeted Therapy in Triple-Negative Breast Cancer
2025PublicationOpen accessFirst authorCorresponding0 citations10.3390/ecsoc-29-26887